Advertisement

Metabolic Brain Disease

, Volume 34, Issue 5, pp 1261–1266 | Cite as

Down-regulation of ERMN expression in relapsing remitting multiple sclerosis

  • Behnaz Salek Esfahani
  • Jalal Gharesouran
  • Soudeh Ghafouri-Fard
  • Shahrzad Talebian
  • Shahram Arsang-Jang
  • Mir Davood Omrani
  • Mohammad TaheriEmail author
  • Maryam RezazadehEmail author
Original Article
  • 106 Downloads

Abstract

Multiple Sclerosis (MS) is a chronic inflammatory disease causing demyelination and neurodegeneration in the central nervous system (CNS). Although the exact etiology of MS is still unclear, both genetic and environmental elements are regarded as causative factors. Environmental factors can induce a cascade of events in immune system leading to neuronal death and nerve demyelination. This paper aims to compare the peripheral transcript levels of Ermin (ERMN) (a gene with putative role in cytoskeletal rearrangements during myelinogenesis) and Listerin E3 Ubiquitin Protein Ligase 1 (LTN1) (a gene with functions in regulating innate immune system) between relapsing-remitting MS (RR-MS) patients and healthy controls. The results showed a significant decrease in ERMN expression (p = 0.022); whereas, no significant difference was detected in LTN1 expression between two groups (p = 0.935). The reduction in ERMN expression in leukocytes could be the cause of demyelinating process in RR-MS patients. Current findings might also have practical importance in prognosis and targeted therapies.

Keywords

Multiple sclerosis (MS) ERMN LTN1 Myelination 

Notes

Acknowledgements

The current study was supported by a grant from Tabriz University of Medical Sciences.

Compliance with ethical standards

Conflict of interest

The authors declare they have no conflict of interest.

References

  1. Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97:742–768CrossRefGoogle Scholar
  2. Bengtson MH, Joazeiro CAP (2010) Role of a ribosome-associated E3 ubiquitin ligase in protein quality control. Nature 467:470–473CrossRefGoogle Scholar
  3. Brockschnieder D, Sabanay H, Riethmacher D, Peles E (2006) Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology. J Neurosci 26:757–762CrossRefGoogle Scholar
  4. Choe Y-J, Park S-H, Hassemer T, Körner R, Vincenz-Donnelly L, Hayer-Hartl M, Hartl FU (2016) Failure of RQC machinery causes protein aggregation and proteotoxic stress. Nature 531:191–195CrossRefGoogle Scholar
  5. Chu J, Hong NA, Masuda CA, Jenkins BV, Nelms KA, Goodnow CC, Glynne RJ, Wu H, Masliah E, Joazeiro CAP, Kay SA (2009) A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc Natl Acad Sci 106:2097–2103CrossRefGoogle Scholar
  6. Defenouillère Q, Zhang E, Namane A, Mouaikel J, Jacquier A, Fromont-Racine M (2016) Rqc1 and Ltn1 prevent C-terminal Alanine-Threonine Tail (CAT-tail)-induced protein aggregation by efficient recruitment of Cdc48 on stalled 60S subunits. J Biol Chem 291:12245–12253CrossRefGoogle Scholar
  7. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545–558CrossRefGoogle Scholar
  8. Di Filippo M, Portaccio E, Mancini A, Calabresi P (2018) Multiple scle- rosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci. 19(10):599-609.  https://doi.org/10.1038/s41583-018-0053-9.
  9. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA (2016) Multiple sclerosis epidemiology in East Asia, south East Asia and South Asia: a systematic review. Neuroepidemiology 46:209–221CrossRefGoogle Scholar
  10. Friese MA, Schattling B, Fugger L (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10:225CrossRefGoogle Scholar
  11. Homs A, Codina-Solà M, Rodríguez-Santiago B, Villanueva C, Monk D, Cuscó I, Pérez-Jurado L (2016) Genetic and epigenetic methylation defects and implication of the ERMN gene in autism spectrum disorders. Transl Psychiatry 6:e855CrossRefGoogle Scholar
  12. Huang WJ, Chen WW, Zhang X (2017) Multiple sclerosis: pathology, diagnosis and treatments. Exp Ther Med 13:3163–3166CrossRefGoogle Scholar
  13. Lassmann H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585:3715–3723CrossRefGoogle Scholar
  14. Lehmann ML, Weigel TK, Elkahloun AG, Herkenham M (2017) Chronic social defeat reduces myelination in the mouse medial prefrontal cortex. Sci Rep 7:46548CrossRefGoogle Scholar
  15. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW (2009a) Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:151–163CrossRefGoogle Scholar
  16. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, Maccarrone G, Turck CW, Dias-Neto E (2009b) Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275–289CrossRefGoogle Scholar
  17. Mazdeh M, Taheri M, Sayad A, Bahram S, Omrani MD, Movafagh A, Inoko H, Akbari MT, Noroozi R, Hajilooi M (2016) HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis. Pharmacogenomics 17:489–498CrossRefGoogle Scholar
  18. Pérez-Cerdá F, Sánchez-Gómez MV, Matute C (2016) The link of inflammation and neurodegeneration in progressive multiple sclerosis. Mult Scler Demyelinating Disord 1:9CrossRefGoogle Scholar
  19. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefGoogle Scholar
  20. Rahimi M, Aghabozorg Afjeh SS, Omrani MD, Arsang-Jang S, Ganji M, Noroozi R, Taheri M, Ghafouri-Fard S (2018) Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in multiple sclerosis patients treated with Interferon beta-1a. Cell Physiol Biochem 46:561–567CrossRefGoogle Scholar
  21. Sawcer S, Franklin RJM, Ban M (2014) Multiple sclerosis genetics. Lancet Neurol 13:700–709CrossRefGoogle Scholar
  22. Sayad A, Ghafouri-Fard S, Omrani MD, Noroozi R, Taheri M (2017) Myxovirus resistance protein A (MxA) polymorphism is associated with IFNbeta response in Iranian multiple sclerosis patients. Neurol Sci 38:1093–1099CrossRefGoogle Scholar
  23. Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B (2010) Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol 176:1878–1890CrossRefGoogle Scholar
  24. Wang T, Jia L, Lv B, Liu B, Wang W, Wang F, Yang G, Bu X, Yao L, Zhang B (2011) Human Ermin (hErmin), a new oligodendrocyte-specific cytoskeletal protein related to epileptic seizure. Brain Res 1367:77–84CrossRefGoogle Scholar
  25. Wang F, Canadeo LA, Huibregtse JM (2015) Ubiquitination of newly synthesized proteins at the ribosome. Biochimie 114:127–133CrossRefGoogle Scholar
  26. Xu H (2014) Neurodegenerative mechanisms of multiple sclerosis. JSM Neurosurg Spine 2:1024Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical Genetics, Faculty of MedicineTabriz University of Medical SciencesTabrizIran
  2. 2.Department of Medical Genetics, School of MedicineShahid Beheshti University of Medical SciencesTehranIran
  3. 3.Clinical Research Development Center (CRDU)Qom University of Medical SciencesQomIran
  4. 4.Urogenital Stem Cell Research CenterShahid Beheshti University of Medical SciencesTehranIran
  5. 5.Immunology Research CenterTabriz University of Medical SciencesTabrizIran

Personalised recommendations